2. PROTAC Protein Tyrosine Kinase/RTK Vitamin D Related/Nuclear Receptor Apoptosis
  3. PROTACs Src Estrogen Receptor/ERR Apoptosis
  4. BY13

BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model. Pink: SRC-3 ligand (SI-2) (HY-101447); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-176226)

For research use only. We do not sell to patients.

BY13 Chemical Structure

BY13 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BY13 Related Antibodies

Top Publications Citing Use of Products

View All PROTACs Isoform Specific Products:

View All Isoforms
von Hippel-Lindau (VHL) Cereblon MDM2 cIAP1

View All Src Isoform Specific Products:

View All Isoforms
Lck Fyn Blk Hck Lyn Yes SRC-3

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms
Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model[1]. Pink: SRC-3 ligand (SI-2) (HY-101447); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-176226)

IC50 & Target

ERα

 

SRC-3

0.031 μM (DC50)

In Vitro

BY13 (0.1-10 μM, 24 h) dose-dependently reduces SRC-3 and ERα protein level in MCF-7 cells with 71% and 85% degradation, respectively[1].
BY13 (0.01-10 μM, 36 h) potently inhibits proliferation of wild-type, mutant-type and drug-resistant breast cancer cells (IC50 of 0.003-0.35 μM for MCF-7, LCC2 and MCF-7D538G/Y537S/EGFR cells), and dose-dependently degrades SRC-3 and ERα in mutant-type cells (particularly in MCF-7Y537S cells at 0.1 μM)[1].
BY13 (0.1-10 μM, 3-48 h) effectively reduces SRC-3 and ERα protein level, superior to Fulvestrant (HY-13636), and reaches the maximal degradation after 36 h while almost no longer increase with time in LCC2 cells [1].
BY13 (0.01-20 μM, 36 h) dramatically decreases the protein level of SRC-3 (0.1 μM only) and ERα (1 μM only) (DC50 of 0.031 μM for SRC-3) with subtype selectivity favoring SRC-1 over SRC-2 in MCF-7 cells[1].
BY13 (0.01-5 μM, 24 h) down-regulates the protein level of AR while this effect is weaker compared to ERα in MCF-7 cells, and moderately inhibits AR-overexpressing LNCaP cells (IC50: 1.43 μM)[1].
BY13 (1 μM, 36 h) significantly reduces SRC-3 protein level depending on a ubiquitin proteasome system (UPS) pathway in MCF-7 cells (similar phenomena observed in LCC2 cells)[1].
BY13 (1 μM, 6 h, 40-76℃) can enter tumor cells and directly bind to SRC-3 with significantly enhancement of the SRC-3 protein thermal stability at high temperature in MCF-7 cells[1].
BY13 (10 μM, 6 h) induces the spatial proximity of SRC-3 and CRBN, followed by promoting the formation of the SRC-3-BY13-CRBN ternary complex in MCF-7 cells[1].
BY13 (0.01-10 μM, 36 h) significantly increases the mRNA expression of SRC-3 with the increasing concentrations and effectively reduces the mRNA level of ERα in LCC2 cells[1].
BY13 (1-20 μM, 48 h) significantly induces breast cancer cells apoptosis with enhancement of both early and late apoptosis in MCF-7 and LCC2 cells.
BY13 (5-20 μM, 48 h) dose-dependently arrests LCC2 cells in the G1 phase, and thecell proportion is significantly higher than that in the S phase.
BY13 (0.01-100 μM) has sufficient metabolic stability and an acceptable safety profile with IC50 of 2.73 and 1.1 μM for CYP3A4 and hERG channel.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BY13 Related Antibodies

Western Blot Analysis[1]

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 0.01, 0.1, 1, 5, 10 μM
Incubation Time: 24 h
Result: Degraded both SRC-3 and ERα protein in MCF-7 cells at 1 μM with 71% and 85% degradation, respectively.
Dose-dependently reduced SRC-3 and ERα protein level in MCF-7 cells without a canonical “hook effect” as well as significantly degrades SRC-3 and ERα in LCC2 cells, superior to Fulvestrant (HY-13636).
Down-regulated the protein level of AR while this effect is weaker compared to ERα in MCF-7 cells

Western Blot Analysis[1]

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 1 μM
Incubation Time: MCF-7 cells (3, 6, 9, 12, 24, 36 h), LCC2 cells (3, 6, 9, 12, 24, 36, 48 h)
Result: Effectively reduced the SRC-3 protein level after 24h and reached the maximal degradation in MCF-7 cells at 36 h. Significantly reduced the protein level of SRC-3 after only 9 h of treatment, and reached the maximal degradation in LCC2 cells at 36 h with almost no longer increase of degradation.

Western Blot Analysis[1]

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 1 μM after 1 μM of MG-132, Bortezomib, Chloroquine or (BY13-Neg, SI-2 and Pomalidomide) for 2 h
Incubation Time: 36 h
Result: Significantly reduced SRC-3 protein level depending on a ubiquitin proteasome system (UPS) pathway, but this effect was reversed by two proteasome inhibitors (MG-132, Bortezomib and SI-2) not by BY13-Neg in MCF-7 cells (similar symptoms observed in LCC2 cells).

Apoptosis Analysis[1]

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 1, 5, 10, 20 μM
Incubation Time: 48 h
Result: Effectively induced cell apoptosis with enhancement of both early and late apoptosis in MCF-7 cells at increased concentrations (35% maximal early apoptosis rate).
Mainly induced the late apoptosis at 1 μM, but resulted in early apoptosis at 10 μM and induced a strong early apoptotic effect at 20 μM (＞ 30% early apoptosis rate) in LCC2 cells.
Parmacokinetics
Species Dose SampleTime Route Indicator value
Mice 2 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.v. T1/2 3.44 hr
Mice 20 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h p.o. T1/2 4.49 hr
Mice 4 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.p. T1/2 3.46 hr
Mice 2 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.v. Cmax 147.85 ng/mL
Mice 20 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h p.o. Tmax 0.33 hr
Mice 4 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.p. Tmax 0.33 hr
Mice 2 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.v. AUC0-t 318.39 ng·h/mL
Mice 20 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h p.o. Cmax 25.44 ng/mL
Mice 4 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.p. Cmax 31.19 ng/mL
Mice 2 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.v. AUC0-∞ 367.1 ng·h/mL
Mice 20 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h p.o. AUC0-t 47.07 ng·h/mL
Mice 4 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.p. AUC0-t 49.14 ng·h/mL
Mice 20 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h p.o. AUC0-∞ 58.39 ng·h/mL
Mice 4 mg/kg 0.167, 0.333, 0.5, 0.75, 1, 2, 3, 6, 9, 24, 48 h i.p. AUC0-∞ 55.19 ng·h/mL
In Vivo

BY13 (3-10 μM/kg, i.p., once every two days for 23  days) has strong antiendocrine-resistant activity through targeting the SRC-3 and ERα degradation with a high safety property, and improves the poor prognosis of endocrine-resistant breast cancer in LCC2 xenograft mice model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Balb/c nude mice (4 weeks old) were injected subcutaneously into the right lower axilla with LCC2 cells (5 × 106 cells/mouse) to induce LCC2 xenograft mice model[1].
Dosage: 3, 5 10 μM/kg, Tamoxifen (10 μM/kg) and Fulvestrant (5 μM/kg)
Administration: i.p., once every two days for 23  days after tumors reached approximately 100 mm3, and then collected sample at 36 day1.
Result: Significantly inhibited tumor growth at 3 μM/kg, with superior effect of 54% tumor growth inhibition rate 54% at 5 μM/kg.
Almost completely degraded SRC-3 protein within the tumor tissues at 3 μM/kg, and the protein levels of both SRC-3 and ERα were further decreased at 5 μM/kg.
Had a wide therapeutic window, without effect weight gain of mice model up to 10 μM/kg.
Had a high safety property without observable histopathological changes in the organ tissues of mice model during the administration period at 3 and 5 μM/kg.
Improved the poor prognosis of endocrine-resistant breast cancer with reducement of ki67 level in tumor tissues at 3 and 5 μM/kg.
Molecular Weight

645.71

Formula

C35H35N9O4
SMILES

C/C(C1=NC=CC=C1)=N\NC2=NC(C=CC=C3)=C3N2C4CN(C4)C5CCN(CC5)C6=CC=CC7=C6C(N(C7=O)C8C(NC(CC8)=O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BY13 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BY13BY 13BY-13PROTACsSrcEstrogen Receptor/ERRApoptosisPROTACDegradationSRC-3ERαAntidrug-resistant breast cancer activitiesMCF-7 cellsLCC2 cellsLCC2 xenograft mice modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BY13
Cat. No.:
HY-176225
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.